Uploaded January 2026 | Updated September 2026, 3 days ago
Type 2 diabetes in children and adolescents is rising rapidly worldwide, and treatment options have been limited… until now.
Dr Tamara S. Hannon (University of Indiana) and Dr Martin Wabitsch (University Hospital Ulm, Germany) sit down with EASD TV host, Vivienne Parry to discuss the SURPASS-PEDS trial, which evaluated tirzepatide, a dual GLP-1 and GIP receptor agonist, in adolescents with type 2 diabetes. Key findings include:
- Hemoglobin A1C reduction: 2.2 percentage points
- Weight loss: ~10% of body weight over 52 weeks
- Tirzepatide both halts excessive weight gain typical in adolescence and promotes metabolic improvement, addressing core drivers of the disease.
The trial highlights the importance of early, tailored interventions in youth, considering both metabolic and psychosocial challenges. Tirzepatide shows promise as a transformative therapy that could slow disease progression, reduce complications, and improve quality of life.
Watch the full discussion to learn why SURPASS-PEDS represents a major step forward in treating type 2 diabetes in young people.
Type 2 diabetes in children and adolescents is rising rapidly worldwide, and treatment options have been limited… until now.
Dr Tamara S. Hannon (University of Indiana) and Dr Martin Wabitsch (University Hospital Ulm, Germany) sit down with EASD TV host, Vivienne Parry to discuss the SURPASS-PEDS trial, which evaluated tirzepatide, a dual GLP-1 and GIP receptor agonist, in adolescents with type 2 diabetes. Key findings include:
- Hemoglobin A1C reduction: 2.2 percentage points
- Weight loss: ~10% of body weight over 52 weeks
- Tirzepatide both halts excessive weight gain typical in adolescence and promotes metabolic improvement, addressing core drivers of the disease.
The trial highlights the importance of early, tailored interventions in youth, considering both metabolic and psychosocial challenges. Tirzepatide shows promise as a transformative therapy that could slow disease progression, reduce complications, and improve quality of life.
Watch the full discussion to learn why SURPASS-PEDS represents a major step forward in treating type 2 diabetes in young people.
